Quick Answer
Amylyx Pharmaceuticals, Inc. reported Stockholders Equity of $305.26 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $305.26M | +85.3% |
| 2024 | $164.76M | -62.0% |
| 2023 | $433.43M | +27.3% |
| 2022 | $340.61M | +325.3% |
| 2021 | -$151.17M | -126.6% |
| 2020 | -$66.72M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $332.00M | +69.2% | +97.8% |
| June 30, 2025 | $167.88M | -35.8% | -16.7% |
| March 31, 2025 | $201.42M | -37.9% | +22.2% |
| December 31, 2024 | $164.76M | -62.0% | -16.0% |
| September 30, 2024 | $196.20M | -53.1% | -24.9% |
| June 30, 2024 | $261.31M | -32.4% | -19.5% |
| March 31, 2024 | $324.44M | -8.0% | -25.1% |
| December 31, 2023 | $433.43M | +27.3% | +3.6% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +85.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Amylyx Pharmaceuticals, Inc.’s stockholders equity has grown by 557.5% (from -$66.72 million to $305.26 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: